GSMA: US Gets Set To Clash with Europe at WRC-19
24.10.2019 10:00:00 EEST | Business Wire | Press release
A clash between the US and Europe over 5G’s future development at The World Radiocommunication Conference 2019 (WRC-19) – taking place in Egypt from 28 October to 22 November 2019 – could risk $565bn of economic expansion globally over the next 15 years, warned the GSMA today.
This economic growth from next-generation 5G services depends on the availability of a specific strand of radio frequencies, known as ‘millimetre wave’ frequencies, which are set to be identified for use by mobile operators at WRC-19. However, efforts by Europe to constrain the use of these critical frequencies due to claims of potential interference with some space services has 5G’s future hanging in the balance.
“The stakes are high - a new generation of 5G services and the economic growth accompanying them will depend on the spectrum decisions taken at WRC-19,” said Brett Tarnutzer, Head of Spectrum, GSMA. “We are calling for Europe to join the US in taking a pro-5G stance at WRC-19 to protect its digital future. Some administrations are still determined to limit mobile use of airwaves that 5G requires to reach its full potential. This protectionist attitude will have consequences for our global economy if allowed to prevail.”
“Our focus is on ensuring that all regions are on board with the win-win resolution that will allow for robust 5G deployments globally while protecting satellite interests worldwide,” said Tom Power, Senior Vice President & General Counsel, CTIA. “Reports indicate that the fastest 5G peak speeds today are in the US, and that’s because the US was the first to deploy mmWave. The benefits of using this spectrum are clear but only through global harmonization at WRC-19 will all regions gain the greatest value.”
Benefits of mmWave spectrum
mmWave bands are critical to providing ultra-high speeds and ultra-high capacity for a wide range of consumer, business and government services that require almost instantaneous delivery of large amounts of data. This includes entertainment services such as downloading ultra-high definition movies in seconds, virtual and augmented reality applications, remote surgery with ‘haptic’ feedback, precise control of industrial devices and robots, and autonomous vehicles.
Three thousand delegates from over 190 nations will meet at WRC-19 to agree on how this spectrum may be used. Different countries may have different approaches and strategies, but WRC is the meeting point for all nations to maximize the potential for 5G within their borders by thinking globally. The process of harmonization at WRC-19 delivers global roaming and economies of scale for vendors and carriers, and that translates into lower costs, faster deployments and greater convenience for consumers.
Clash over airwaves at WRC-19
The build-up to WRC-19 is a four-year process and the use of mmWave spectrum has been the subject of intense technical study throughout. WRC-19 is the final decision after a lot of analysis and technical study.
Technical studies supported by the Americas, Africa and Arab states, have demonstrated that 5G using mmWave spectrum can co-exist safely and efficiently alongside weather-sensing services, commercial satellite services and others. These were conducted within the ITU, a UN agency. In the US, the FCC developed emission limits on 5G to protect weather sensors in nearby spectrum bands. Ahead of WRC-19, the FCC and the State Department also worked with regulators from other countries throughout the Americas, achieving consensus at the CITEL conference in Ottawa in August.
Despite this body of evidence, European countries are looking to limit the use of mmWave spectrum by setting protective technical conditions.
“It is important to follow studies which make realistic assumptions about how networks will function and make the best use of the spectrum for all,” added Brett Tarnutzer. This approach is being followed in the Americas, Africa and the Middle East but we need to find a global solution, including Europe. Large ‘guard bands’ will be needed – that is empty tranches of unused spectrum separating services - if we have technical limits which are too severe. This will restrict the economic benefit we can gain from finite spectrum resources and harm consumers and industry.”
-ENDS-
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators with over 350 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.
For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191024005025/en/
Contact information
Media Contacts:
For the GSMA
Gearóid Cashman
+44 79 7679 0169
gcashman@webershandwick.com
GSMA Press Office
pressoffice@gsma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
